These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 29589675)

  • 41. Peritoneal carcinomatosis from unusual cancer origins: Is there a role for hyperthermic intraperitoneal chemotherapy?
    Honoré C; Goéré D; Macovei R; Colace L; Benhaim L; Elias D
    J Visc Surg; 2016 Apr; 153(2):101-7. PubMed ID: 26698380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
    Vaira M; Robella M; Mellano A; Sottile A; De Simone M
    Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
    World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postoperative Complications Independently Predict Cancer-Related Survival in Peritoneal Malignancies.
    Choudry MHA; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Dec; 25(13):3950-3959. PubMed ID: 30302637
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A minimally invasive approach for peritonectomy procedures and hyperthermic intraperitoneal chemotherapy (HIPEC) in limited peritoneal carcinomatosis: The American Society of Peritoneal Surface Malignancies (ASPSM) multi-institution analysis.
    Arjona-Sanchez A; Esquivel J; Glehen O; Passot G; Turaga KK; Labow D; Rufian-Peña S; Morales R; van der Speeten K
    Surg Endosc; 2019 Mar; 33(3):854-860. PubMed ID: 30003349
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC).
    Fisher SB; Rafeeq S; Hess K; Grotz TE; Mansfield P; Royal R; Badgwell B; Fleming J; Fournier K; Mann GN
    J Surg Oncol; 2018 Mar; 117(4):685-691. PubMed ID: 29193085
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
    Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
    Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIPEC plus EPIC paclitaxel for maximal perioperative treatments of advanced epithelial ovarian cancer. Long-term results of a pilot study.
    Sugarbaker PH; Stuart OA
    Surg Oncol; 2020 Dec; 35():441-446. PubMed ID: 33039850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: long-term results at St George Hospital, Australia.
    Alzahrani N; Ferguson JS; Valle SJ; Liauw W; Chua T; Morris DL
    ANZ J Surg; 2016 Nov; 86(11):937-941. PubMed ID: 26179296
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ninety-day post-operative morbidity and mortality using the National Cancer Institute's common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Alyami M; Kim BJ; Villeneuve L; Vaudoyer D; Képénékian V; Bakrin N; Gilly FN; Cotte E; Glehen O; Passot G
    Int J Hyperthermia; 2018 Aug; 34(5):532-537. PubMed ID: 28838265
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
    López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
    Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and HIPEC: preliminary results in highly selected patients.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):551-8. PubMed ID: 24193287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.
    Dazza M; Schwarz L; Coget J; Frebourg N; Wood G; Huet E; Bridoux V; Veber B; Tuech JJ
    World J Surg; 2016 Dec; 40(12):3035-3043. PubMed ID: 27412631
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
    Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictors of Severe Morbidity After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Patients With Colorectal Peritoneal Carcinomatosis.
    Simkens GA; van Oudheusden TR; Luyer MD; Nienhuijs SW; Nieuwenhuijzen GA; Rutten HJ; de Hingh IH
    Ann Surg Oncol; 2016 Mar; 23(3):833-41. PubMed ID: 26442921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Major Postoperative Complications Are a Risk Factor for Impaired Survival after CRS/HIPEC.
    Schneider MA; Eshmuminov D; Lehmann K
    Ann Surg Oncol; 2017 Aug; 24(8):2224-2232. PubMed ID: 28265776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repeated cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from appendiceal cancer: analysis of survival outcomes.
    Sardi A; Jimenez WA; Nieroda C; Sittig M; Macdonald R; Gushchin V
    Eur J Surg Oncol; 2013 Nov; 39(11):1207-13. PubMed ID: 24007834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry.
    Votanopoulos KI; Sugarbaker P; Deraco M; Morris D; Glehen O; Elias D; De Simone M; Robella M; Heyd B; Kusamura S; Baratti D; Chouliaras K; Russell G; Shen P; Levine EA;
    Ann Surg Oncol; 2018 Mar; 25(3):667-673. PubMed ID: 29260418
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients.
    Piso P; Nedelcut SD; Rau B; Königsrainer A; Glockzin G; Ströhlein MA; Hörbelt R; Pelz J
    Ann Surg Oncol; 2019 Jan; 26(1):148-154. PubMed ID: 30456672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.